News 23.03.2022 Zurich-Schlieren, Switzerland, March 23rd, 2022. TOPADUR Pharma AG, a clinical-stage biopharmaceutical start-up company developing first-in-class drugs for aging diseases, today announced that the European Patent Office (EPO) granted a patent covering its lead investigational drug product, TOP-N53 used for the treatment of chronic wounds. The European patent covers composition of matter for...
Events, External events
Event date: 29.04.2022
You learn about the cornerstones of a communications strategy that fits to your business strategy and the development stage of your company. We will explore on how to craft a convincing company positioning and a set of strong key messages. We will also discuss on how to make best use...
Events, External events
Event date: 22.04.2024
Program: https://swissbiotechday.ch/program-2024/
Registration: https://swissbiotechday.ch/registration-2024/
The Swiss Biotech Day is a premier biotechnology conference in Europe, attracting professionals from the global life sciences community. In 2024, it will once again provide a platform for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing. International...
News 16.03.2022 Financial highlights CHF 30.7 million cash & cash equivalents, trade and other receivables at December 31, 2021 Product sales increased more than 100% to CHF 8.3 million Received USD 6 million (CHF 5.5 million) milestone payments from Checkmate Pharmaceuticals Received USD 7 million (CHF 6.4 million) up front with USD...
News 16.03.2022 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built proteins known as DARPin therapeutics, today announced its corporate highlights and audited financial results for 2021. Research...